Squamous Non-Small Cell Lung Cancer Therapeutics Market to Hit $8.06 Billion by 2031, Driven by Cancer Treatment & Immunotherapy

Leander, Texas and Tokyo, Japan - Dec.09.2025
As per DataM intelligence research report" The Global Squamous Non-Small Cell Lung Cancer Therapeutics Market reached US$4 billion in 2023 and is expected to reach US$ 8.06 billion by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031." Next-gen immuno-oncology solutions are enhancing treatment options for squamous NSCLC.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/squamous-non-small-cell-lung-cancer-therapeutics-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, The FDA granted accelerated approval to a new targeted therapy for squamous NSCLC with FGFR alterations. The drug showed promising response rates in patients who had progressed on chemotherapy. It offers a precision medicine option for a subtype that historically lacked targets.

✅ In October 2025, Merck presented data on a Pembrolizumab-based combination therapy for early-stage squamous NSCLC. The neoadjuvant regimen significantly improved event-free survival in resectable patients. It moves immunotherapy into earlier lines of treatment for U.S. patients.

✅ In September 2025, Mirati Therapeutics (Bristol Myers Squibb) updated results for Adagrasib in KRAS-mutated squamous lung cancer. The data confirmed the drug's efficacy in non-adenocarcinoma histologies. It expands the potential patient population for KRAS inhibitors.

✅ In August 2025, A U.S. oncology consortium launched a "Squamous Lung Master Protocol" (Lung-MAP) sub-study. The trial tests multiple investigational drugs matched to specific genomic profiles. It accelerates the development of personalized therapies for squamous cell carcinoma.

Japan: Recent Industry Developments

✅ In December 2025, Chugai Pharmaceutical received approval for a Tecentriq combination for adjuvant treatment of squamous NSCLC. The approval provides a new option to prevent recurrence after surgery. It strengthens the standard of care for Japanese post-operative patients.

✅ In November 2025, Daiichi Sankyo initiated a Phase 3 trial of its TROP2-directed ADC in Japanese squamous NSCLC patients. The drug targets a protein highly expressed in squamous cell tumors. It leverages Japan's leadership in antibody-drug conjugate development.

✅ In October 2025, The National Cancer Center Japan published a study on the genomic landscape of Japanese squamous lung cancer. The research identified unique mutation patterns compared to Western populations. It guides the development of localized therapeutic strategies.

✅ In September 2025, Ono Pharmaceutical launched a patient support program for those on Opdivo therapy for squamous NSCLC. The program provides digital tools to track side effects and adherence. It improves the management of immunotherapy in Japanese clinical practice.

Squamous Non-Small Cell Lung Cancer Therapeutics Market: Drivers
The therapeutics market for squamous non-small cell lung cancer (NSCLC) is advancing as immunotherapies, targeted agents, and combination regimens improve survival and response rates for a traditionally hard-to-treat histology. Checkpoint inhibitors have become foundational in many treatment lines, often combined with chemotherapy or anti-angiogenic agents to enhance efficacy. Ongoing research into biomarkers, novel targets, and resistance mechanisms is expanding the pipeline of targeted small molecules and antibody-based therapies. Enhanced molecular profiling and patient stratification are enabling more precise therapeutic choices and clinical trial enrollment.

Pharma and biotech investments are focused on overcoming resistance, improving tolerability, and sequencing therapies to maximize patient benefit. Integration of radiotherapy, surgery, and systemic options in multidisciplinary care pathways continues to refine outcomes. Real-world evidence and broader access programs are helping extend novel therapies to diverse patient populations. With sustained R&D and regulatory support, the squamous NSCLC therapeutics landscape is poised for continued improvement in patient outcomes.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/squamous-non-small-cell-lung-cancer-therapeutics-market?Prasad

Squamous Non-Small Cell Lung Cancer Therapeutics Market: Major Players
Genentech, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG, Merck Sharp & Dhome Corporation, Breckenridge Pharmaceutical Inc., Teva Pharmaceuticals Inc., Apotex Corporation among others.

Segment Covered in the Squamous Non-Small Cell Lung Cancer Therapeutics Market:
By Therapy Type
The market is segmented into targeted therapy 35%, immunotherapy 30%, chemotherapy 25%, and others 10%, with targeted therapy dominating due to precision medicine, better patient outcomes, and increasing molecular diagnostics. Immunotherapy adoption is growing rapidly with checkpoint inhibitors and combination regimens. Chemotherapy remains widely used as standard treatment. Other therapies include emerging experimental and combination treatments supporting niche adoption.

By End-User
End-users include hospitals 60%, specialty clinics 30%, and others 10%, with hospitals dominating due to high patient load, specialized oncology departments, and advanced treatment facilities. Specialty clinics focus on targeted therapies and immunotherapy administration. Other end-users include research centers and home-care oncology services. High adoption in hospitals ensures wide patient reach and treatment continuity.

Regional Analysis
North America - 40% Share
North America leads with 40% share driven by high NSCLC prevalence, advanced healthcare infrastructure, and strong R&D in the U.S. and Canada. Targeted therapy and immunotherapy dominate. Hospitals are the primary end-users. Advanced diagnostics and personalized treatment approaches drive market growth.

Europe - 25% Share
Europe holds 25% share due to rising lung cancer incidence, early diagnosis, and robust healthcare systems in Germany, UK, and France. Targeted therapy dominates, followed by immunotherapy. Hospitals and specialty clinics are key end-users. Personalized and precision medicine adoption supports growth.

Asia Pacific - 20% Share
Asia Pacific accounts for 20% share driven by increasing NSCLC cases, improving healthcare access, and growing adoption of targeted and immunotherapies in China, Japan, India, and Australia. Targeted therapy is widely adopted. Hospitals are primary end-users. Rising awareness and cancer screening programs support market growth.

Latin America - 8% Share
Latin America holds 8% share supported by increasing lung cancer awareness and improving oncology infrastructure in Brazil, Mexico, and Argentina. Targeted therapy dominates. Hospitals are the main end-users. Specialty clinics are gradually increasing adoption. Government initiatives for cancer care drive growth.

Middle East - 4% Share
The Middle East records 4% share due to rising NSCLC incidence and improving healthcare infrastructure in Gulf countries. Targeted therapy dominates, with growing immunotherapy adoption. Hospitals are primary end-users. Oncology awareness campaigns support adoption.

Africa - 3% Share
Africa holds 3% share due to limited healthcare infrastructure, low screening rates, and restricted access to advanced therapies in South Africa, Nigeria, and Egypt. Targeted therapy dominates. Hospitals are primary end-users, with specialty clinics gradually emerging. Awareness and healthcare improvements are expected to support growth.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=squamous-non-small-cell-lung-cancer-therapeutics-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.